Children's toxicology from bench to bed - Drug-induced Renal Injury (2): Nephrotoxiciy induced by cisplatin and ifosfamide in children

Journal of Toxicological Sciences

Volumn 34, Issue 2 SPEC. ISS., 2009, Pages

  Fujieda, Mikiya ^a   Matsunaga, Akira ^b   Hayashi, Atsushi ^c   Tauchi, Hiromichi ^d   Chayama, Kohsuke ^e   Sekine, Takashi ^f  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

^d EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e OKAYAMA UNIVERSITY   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

Author keywords

Carboplatin; Children; Cisplatin; Hypouremia; Ifosfamide; Nephrotoxicity

Indexed keywords

ACROLEIN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CIMETIDINE; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; MESNA; URIC ACID; VINCRISTINE;

ACUTE KIDNEY FAILURE; ADOLESCENT; AGE; AMINOACIDURIA; AREA UNDER THE CURVE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BRAIN TUMOR; CALCIUM URINE LEVEL; CANCER REGRESSION; CHILD; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL FEATURE; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DIABETES INSIPIDUS; DISEASE DURATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; FANCONI RENOTUBULAR SYNDROME; FEMALE; GERM CELL TUMOR; GLUCOSURIA; GROWTH DISORDER; HEMORRHAGIC CYSTITIS; HODGKIN DISEASE; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOCALCIURIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; HYPOPHOSPHATEMIC RICKETS; HYPOURICEMIA; INCIDENCE; KIDNEY TUBULE ACIDOSIS; KIDNEY TUBULE DISORDER; KIDNEY TUBULE NECROSIS; LEUKOCYTE COUNT; MAGNESIUM BLOOD LEVEL; MAGNESIUM URINE LEVEL; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RECORD REVIEW; MEDICAL RESEARCH; NATRIURESIS; NEPHRECTOMY; NEPHROBLASTOMA; NEPHROTOXICITY; NEUROBLASTOMA; OSTEOSARCOMA; PATHOPHYSIOLOGY; PREDICTOR VARIABLE; PRESCHOOL CHILD; PROGNOSIS; PROTEINURIA; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; SIDE EFFECT; SOLID TUMOR; URIC ACID BLOOD LEVEL;

EID: 67651180868     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.34.SP251     Document Type: Conference Paper

References (18)

1. Ariceta, G., Rodriguez-Soriano, J., Vallo, A. and Navajas, A. (1997): Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med. Pediatr. Oncol., 28, 35-40.
2. Ciarimboli, G., Ludwig, T., Lang, D., Pavenstädt, H., Koepsell, H., Piechota, H.J., Haier, J., Jaehde, U., Zisowsky, J. and Schlatter, E. (2005): Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol., 167, 1477-1484.
3. Corbett, R., Pinkerton, R., Pritchard, J., Meller, S., Lawis, I., Kingston, J. and McElwain, T. (1992): Pilot study of high-dose vincristine, etoposide, carboplatin and melphalan with autologous bone marrow rescue in advanced neuroblastoma. Eur. J. Cancer, 28A, 1324-1328.
4. Daugaard, G., Rossing, N. and Rorth, M. (1988): Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother. Pharmacol., 21, 163-167.
5. English, M.W., Skinner, R., Pearson, A.D., Price, L., Wyllie, R. and Craft, A.W. (1999): Dose-related nephrotoxicity of carboplatin in children. Br. J. Cancer, 81, 336-341.
6. Finkel, K.W. and Foringer, J.R. (2007): Renal disease in patients with cancer. Nat. Clin. Pract. Nephrol., 3, 669-678.
7. Kintzel, P.E. (2001): Anticancer drug-induced kidney disorders. Drug Safety, 24, 19-38.
8. Koeller, J.M., Trump, D.L., Tutsch, K.D., Earhart, R.H., Davis, T. E. and Tormey, D.C. (1986): Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30- minute infusion. Cancer, 57, 222-225.
9. Li, Y.F., Fu, S., Hu, W., Liu, J.H., Finkels, K.W., Gershenson, D.M. and Kavanagh, J.J. (2007): Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int. J. Gynecol. Cancer, 17, 739-763.
10. Loebstein, R., Atanackovic, G., Bishai, R., Wolpin, J., Khattak, S., Hashemi, G., Gobrial, M., Baruchel, S., Ito, S. and Koren, G. (1999): Risk factors for long-term outcome of ifosfamide- induced nephrotoxicity in children. J. Clin. Pharmacol., 39, 454-461.
11. Ludwig, T., Riethmuller, C. and Gekle, M. (2004): Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int., 66, 196-202. (Pubitemid 38870095)
12. Pabla, N. and Dong, Z. (2008): Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int., 73, 994-1007. (Pubitemid 351543900)
13. Patzer, L., Hernando, N., Ziegler, U., Beck-Schimmer, B., Biber, J. and Murer, H. (2006): Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells. Kidney Int., 70, 1725-1734. (Pubitemid 44684803)
14. Rossi, R., Kleta, R. and Ehrich, J.H. (1999): Renal involvement in children with malignancies. Pediatr. Nephrol., 13, 153-162.
15. Skinner, R. (2003): Chronic ifosfamide nephrotoxicity in children. Med. Pediatr. Oncol., 41, 190-197.
16. Skinner, R., Cotterill, S.J. and Stevens, M.C. (2000): Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effect Group study. United Kingdom Children's Cancer Study Group. Br. J. Cancer, 82, 1636-1645.
17. Womer, R.B., Pritchard, J. and Barratt, T.M. (1985): Renal toxicity of cisplatin in children. J. Pediatr., 106, 659-663.
18. Zhang, B., Ramesh, G., Norbury, C.C. and Reeves, W.B. (2007): Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int., 72, 37-44. (Pubitemid 47014442)